Beyond Histology: Lowering Human Leukocyte Antigen Antibody to Improve Renal Allograft Survival in Acute Rejection
| Autor: | Paul G. Catrou, Paul I. Terasaki, Kimberly P. Briley, Carl E. Haisch, Miyuki Ozawa, Matthew J Everly, Lorita M. Rebellato |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Graft Rejection Male medicine.medical_specialty Time Factors Biopsy medicine.medical_treatment Down-Regulation Kaplan-Meier Estimate Human leukocyte antigen Gastroenterology chemistry.chemical_compound Adrenal Cortex Hormones HLA Antigens Isoantibodies Internal medicine medicine Humans Transplantation Homologous Survival analysis Antilymphocyte Serum Retrospective Studies Transplantation Creatinine Kidney biology Thymoglobulin business.industry Graft Survival Antibodies Monoclonal Plasmapheresis Middle Aged Kidney Transplantation Treatment Outcome medicine.anatomical_structure chemistry Acute Disease Antibody Formation Immunology biology.protein Drug Therapy Combination Female Antibody business Immunosuppressive Agents Muromonab-CD3 |
| Zdroj: | Transplantation. 89:962-967 |
| ISSN: | 0041-1337 |
| DOI: | 10.1097/tp.0b013e3181cbac02 |
| Popis: | Background. The common endpoint in the treatment of antibody-mediated rejection (AMR) is functional reversal (creatinine levels). Reduction of human leukocyte antigen (HLA) antibody strength is not commonly considered as an essential endpoint for AMR resolution. The purpose of this study was to determine whether reduction in HLA antibody intensity in patients with histologic AMR reversal influences long-term renal allograft survival. Methods. Renal allograft recipients were included if he or she had a biopsy diagnosis of AMR (between August 2000 and October 2008) and serial evaluation for HLA antibodies prebiopsy and postbiopsy. Antibody reduction was defined as mean fluorescence intensity decrease more than 50% in highest intensity antibody after AMR therapy and the absence of new antibody formation. Patients were treated with plasmapheresis, thymoglobulin/OKT3, and corticosteroids. Survival analysis was performed using STATA/MP v10 (College Station, TX). Results. Twenty-eight patients were analyzed. Antibody reduction failed to occur in 22 of 28 cases. Baseline characteristics were similar between groups. Antibody nonresponders had significantly shorter allograft survival time (61.4 months) compared with antibody responders (no failures) (P=0.04, log-rank test). Conclusions. In conclusion, failure to significantly reduce antibody levels and prevent new formation was strongly predictive of allograft loss. This observation suggests that the therapeutic intervention that reduces antibody production may prolong graft survival in transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|